Lansoprazole add-on treatment for idiopathic pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years old or older, and you can give informed consent
- You have idiopathic pulmonary fibrosis (IPF) confirmed by specialists using guideline-based criteria
- If you take anti-fibrotic IPF medicines, you’ve been on the same one for at least 4 weeks before randomization
- You must be able to do study breathing tests (spirometry) reliably
- You cannot take lansoprazole or other proton pump inhibitors (PPIs) or certain related stomach medicines in the 2 weeks before randomization
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.